The strategic collaboration will introduce Eau Thermale Avène and Ducray dermo-cosmetic brands to Kenya, Tanzania, and Uganda, addressing the growing demand for high-quality dermatological solutions in the region....
With plans to commercialize its pancreatic cancer test in the U.S. by late 2025, Immunovia seeks financial leadership with diagnostics expertise and global capital market experience....
With all female patients in its groundbreaking clinical feasibility study reaching six-month primary endpoints, UroMems' UroActive System marks a transformative step in treating stress urinary incontinence. The AI-powered smart implant, designed to enhance patient quality of life, is now paving the way for expanded adoption in the U.S. and Europe. ...
3Shape is celebrating 25 years of innovation by introducing a paradigm shift in CAD workflows for dental labs with the upcoming release of 3Shape Dental System 2024. This new software update will include a free AI-driven crown design application along with several workflow enhancements to significantly improve efficiency and digitization for dental labs. As the first employee hired at 3Shape 25 years ago, Rune Fisker, Senior Vice President of Product Strategy, reflects on the remarkable evolu...
With CE Mark certification, the AI-powered ECGenius System is now approved for commercialization in the European Economic Area, enhancing real-time electrogram recording and clinical decision-making for healthcare providers....
Largest Randomized AI Mammography Study Shows 29% Higher Cancer Detection with 44% Less Screen-Reading Burden...
Breakthrough Neurodiagnostic Device Aims to Transform Early Detection and Treatment of Neurological Disorders Across Europe...
Acquisition strengthens Medtronic’s spine portfolio with cutting-edge nanotechnology, enhancing implant integration, spinal fusion, and surgical success. ...
Breakthrough imaging agent advances prostate cancer diagnostics across Europe....
Santhera has begun launch preparations for AGAMREE® in UK with first sales expected in this quarter ...
